J&J Settles One Risky Opioid Trial on the Cheap

Johnson & Johnson agreed to pay more than $20 million to avoid the first federal trial in which it faced accusations of helping fuel the opioid epidemic by mishandling its painkillers. Under the ...

MS Amlin Exits 9 Core Markets, Refocuses on 3

MS Amlin said it will be exiting nine non-core markets that no longer fit into its long-term strategy. Instead, the London-based insurer and reinsurer and MS&AD subsidiary will pursue a new ...